맞춤형 암 치료 시장 분석 및 예측(-2035년) : 유형별, 제품별, 서비스별, 기술별, 적응 질환별, 최종 사용자별, 배포별, 단계별, 솔루션별

Personalized Cancer Therapies Market is anticipated to expand from $47.5 billion in 2024 to $107.8 billion by 2034, growing at a CAGR of approximately 9.1%. The Personalized Cancer Therapies Market encompasses treatments tailored to individual genetic profiles, enhancing efficacy and minimizing side effects. This market integrates genomics, biotechnology, and advanced diagnostics to develop targeted therapies. As precision medicine gains traction, demand is rising for innovations in biomarker discovery, targeted drugs, and companion diagnostics, driven by the quest for improved patient outcomes and healthcare efficiency.

The Personalized Cancer Therapies Market is evolving rapidly, propelled by advances in genomics and targeted treatment approaches. The immunotherapy segment is the top performer, driven by the success of checkpoint inhibitors and CAR-T cell therapies. These therapies are revolutionizing cancer treatment by harnessing the body's immune system to attack cancer cells. Targeted therapy follows as the second highest performing segment, with kinase inhibitors and monoclonal antibodies offering precise treatment options based on genetic profiles. Precision medicine, which tailors treatment to individual genetic markers, is gaining momentum, enhancing the efficacy of personalized cancer therapies. Companion diagnostics are crucial, providing insights into patient-specific treatment responses and optimizing therapeutic outcomes. The integration of artificial intelligence in drug discovery and development is further accelerating advancements in this market. As personalized approaches become more refined, the focus on patient-centric care is expected to drive continued growth and innovation in cancer treatment strategies.

The Personalized Cancer Therapies Market is witnessing a dynamic shift with a diverse range of new product launches enhancing treatment options. Market share is dominated by innovative therapies that promise tailored treatment regimens, aligning with patient-specific genetic profiles. Pricing strategies are evolving, reflecting the premium nature of these therapies and their potential to significantly improve patient outcomes. The market is characterized by robust competition, with major pharmaceutical companies investing heavily in research and development to maintain a competitive edge. Competition benchmarking reveals a landscape where leading firms are continuously innovating to stay ahead. Regulatory influences are pivotal, with stringent guidelines governing the approval and commercialization of personalized therapies. Policymakers in key regions like North America and Europe are actively shaping the regulatory framework, impacting market dynamics. Analytical insights indicate a growing emphasis on precision medicine, with advancements in genomics and biotechnology driving market expansion. The interplay of competition, regulation, and innovation defines the strategic outlook for stakeholders in this burgeoning field.

Geographical Overview:

The personalized cancer therapies market is witnessing robust growth across various regions, each presenting unique opportunities. North America leads the charge, driven by cutting-edge research and substantial investment in precision medicine. The presence of leading biotechnology firms and advanced healthcare infrastructure further bolsters this region's dominance. Europe follows, with strong government support and a growing emphasis on personalized healthcare solutions. The region's commitment to innovation and patient-centric approaches enhances its market potential. In Asia Pacific, the market is expanding rapidly, propelled by rising cancer prevalence and increasing healthcare expenditure. Countries like China and India are emerging as key growth pockets due to their large patient populations and improving healthcare systems. Meanwhile, Latin America and the Middle East & Africa are gaining traction as emerging markets. In Latin America, initiatives to improve healthcare access and infrastructure are driving market growth. The Middle East & Africa are recognizing the potential of personalized therapies to address unmet medical needs, presenting lucrative opportunities for market expansion.

The personalized cancer therapies market is navigating a landscape shaped by global tariffs, geopolitical tensions, and evolving supply chain dynamics. In Japan and South Korea, trade tensions with major economies are fostering investments in local biotech innovation to mitigate dependency on foreign technologies. China's strategic pivot towards self-sufficiency is accelerating its development of domestic biopharmaceutical capabilities, while Taiwan's robust biotech sector remains vulnerable to geopolitical uncertainties. Globally, the parent market is experiencing robust growth, driven by advancements in precision medicine and genomic research. By 2035, the market's trajectory will hinge on resilient supply chains and cross-border collaborations. Meanwhile, Middle East conflicts could exacerbate global supply chain disruptions and elevate energy prices, influencing manufacturing costs and distribution strategies within the sector.

Key Trends and Drivers:

The personalized cancer therapies market is experiencing robust growth, driven by advances in genomics and biotechnology. Key trends include the increasing adoption of precision medicine approaches, which tailor treatments based on individual genetic profiles. This shift is enhancing treatment efficacy and minimizing adverse effects, significantly improving patient outcomes. Another trend is the integration of artificial intelligence and machine learning in drug discovery and development processes. These technologies are accelerating the identification of novel targets and optimizing treatment regimens. Furthermore, the rise of liquid biopsy techniques is revolutionizing cancer diagnostics, enabling non-invasive monitoring of tumor dynamics and treatment responses. Drivers include a growing prevalence of cancer and a heightened focus on patient-centric healthcare models. Regulatory bodies are also supporting personalized therapies through expedited approval pathways. Opportunities abound for companies that leverage cutting-edge technologies and collaborate with academic and clinical research institutions to develop innovative treatments.

Research Scope:

• Estimates and forecasts the overall market size across type, application, and region.
• Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
• Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
• Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
• Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
• Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
• Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

• 1.1 Market Size and Forecast
• 1.2 Market Overview
• 1.3 Market Snapshot
• 1.4 Regional Snapshot
• 1.5 Strategic Recommendations
• 1.6 Analyst Notes

2 Market Highlights

• 2.1 Key Market Highlights by Type
• 2.2 Key Market Highlights by Product
• 2.3 Key Market Highlights by Services
• 2.4 Key Market Highlights by Technology
• 2.5 Key Market Highlights by Application
• 2.6 Key Market Highlights by End User
• 2.7 Key Market Highlights by Deployment
• 2.8 Key Market Highlights by Stage
• 2.9 Key Market Highlights by Solutions

3 Market Dynamics

• 3.1 Macroeconomic Analysis
• 3.2 Market Trends
• 3.3 Market Drivers
• 3.4 Market Opportunities
• 3.5 Market Restraints
• 3.6 CAGR Growth Analysis
• 3.7 Impact Analysis
• 3.8 Emerging Markets
• 3.9 Technology Roadmap
• 3.10 Strategic Frameworks
  • 3.10.1 PORTER's 5 Forces Model
  • 3.10.2 ANSOFF Matrix
  • 3.10.3 4P's Model
  • 3.10.4 PESTEL Analysis

4 Segment Analysis

• 4.1 Market Size & Forecast by Type (2020-2035)
  • 4.1.1 Monoclonal Antibodies
  • 4.1.2 Cell Therapy
  • 4.1.3 Gene Therapy
  • 4.1.4 Cancer Vaccines
  • 4.1.5 Oncolytic Virus Therapy
  • 4.1.6 Targeted Small Molecules
• 4.2 Market Size & Forecast by Product (2020-2035)
  • 4.2.1 Biologics
  • 4.2.2 Biosimilars
  • 4.2.3 Small Molecule Drugs
  • 4.2.4 Diagnostics
  • 4.2.5 Companion Diagnostics
• 4.3 Market Size & Forecast by Services (2020-2035)
  • 4.3.1 Genomic Profiling
  • 4.3.2 Biomarker Testing
  • 4.3.3 Immunotherapy Services
  • 4.3.4 Clinical Trial Services
  • 4.3.5 Consulting Services
• 4.4 Market Size & Forecast by Technology (2020-2035)
  • 4.4.1 Next-Generation Sequencing
  • 4.4.2 Polymerase Chain Reaction
  • 4.4.3 Mass Spectrometry
  • 4.4.4 Flow Cytometry
  • 4.4.5 Nanotechnology
  • 4.4.6 CRISPR
• 4.5 Market Size & Forecast by Application (2020-2035)
  • 4.5.1 Breast Cancer
  • 4.5.2 Lung Cancer
  • 4.5.3 Colorectal Cancer
  • 4.5.4 Prostate Cancer
  • 4.5.5 Melanoma
  • 4.5.6 Leukemia
• 4.6 Market Size & Forecast by End User (2020-2035)
  • 4.6.1 Hospitals
  • 4.6.2 Cancer Research Centers
  • 4.6.3 Biotechnology Companies
  • 4.6.4 Pharmaceutical Companies
  • 4.6.5 Academic Institutions
• 4.7 Market Size & Forecast by Deployment (2020-2035)
  • 4.7.1 On-premise
  • 4.7.2 Cloud-based
  • 4.7.3 Hybrid
• 4.8 Market Size & Forecast by Stage (2020-2035)
  • 4.8.1 Research and Development
  • 4.8.2 Clinical Trials
  • 4.8.3 Commercialization
  • 4.8.4 Post-Market Surveillance
• 4.9 Market Size & Forecast by Solutions (2020-2035)
  • 4.9.1 Therapeutic Solutions
  • 4.9.2 Diagnostic Solutions
  • 4.9.3 Predictive Solutions

5 Regional Analysis

• 5.1 Global Market Overview
• 5.2 North America Market Size (2020-2035)
  • 5.2.1 United States
    • 5.2.1.1 Type
    • 5.2.1.2 Product
    • 5.2.1.3 Services
    • 5.2.1.4 Technology
    • 5.2.1.5 Application
    • 5.2.1.6 End User
    • 5.2.1.7 Deployment
    • 5.2.1.8 Stage
    • 5.2.1.9 Solutions
  • 5.2.2 Canada
    • 5.2.2.1 Type
    • 5.2.2.2 Product
    • 5.2.2.3 Services
    • 5.2.2.4 Technology
    • 5.2.2.5 Application
    • 5.2.2.6 End User
    • 5.2.2.7 Deployment
    • 5.2.2.8 Stage
    • 5.2.2.9 Solutions
  • 5.2.3 Mexico
    • 5.2.3.1 Type
    • 5.2.3.2 Product
    • 5.2.3.3 Services
    • 5.2.3.4 Technology
    • 5.2.3.5 Application
    • 5.2.3.6 End User
    • 5.2.3.7 Deployment
    • 5.2.3.8 Stage
    • 5.2.3.9 Solutions
• 5.3 Latin America Market Size (2020-2035)
  • 5.3.1 Brazil
    • 5.3.1.1 Type
    • 5.3.1.2 Product
    • 5.3.1.3 Services
    • 5.3.1.4 Technology
    • 5.3.1.5 Application
    • 5.3.1.6 End User
    • 5.3.1.7 Deployment
    • 5.3.1.8 Stage
    • 5.3.1.9 Solutions
  • 5.3.2 Argentina
    • 5.3.2.1 Type
    • 5.3.2.2 Product
    • 5.3.2.3 Services
    • 5.3.2.4 Technology
    • 5.3.2.5 Application
    • 5.3.2.6 End User
    • 5.3.2.7 Deployment
    • 5.3.2.8 Stage
    • 5.3.2.9 Solutions
  • 5.3.3 Rest of Latin America
    • 5.3.3.1 Type
    • 5.3.3.2 Product
    • 5.3.3.3 Services
    • 5.3.3.4 Technology
    • 5.3.3.5 Application
    • 5.3.3.6 End User
    • 5.3.3.7 Deployment
    • 5.3.3.8 Stage
    • 5.3.3.9 Solutions
• 5.4 Asia-Pacific Market Size (2020-2035)
  • 5.4.1 China
    • 5.4.1.1 Type
    • 5.4.1.2 Product
    • 5.4.1.3 Services
    • 5.4.1.4 Technology
    • 5.4.1.5 Application
    • 5.4.1.6 End User
    • 5.4.1.7 Deployment
    • 5.4.1.8 Stage
    • 5.4.1.9 Solutions
  • 5.4.2 India
    • 5.4.2.1 Type
    • 5.4.2.2 Product
    • 5.4.2.3 Services
    • 5.4.2.4 Technology
    • 5.4.2.5 Application
    • 5.4.2.6 End User
    • 5.4.2.7 Deployment
    • 5.4.2.8 Stage
    • 5.4.2.9 Solutions
  • 5.4.3 South Korea
    • 5.4.3.1 Type
    • 5.4.3.2 Product
    • 5.4.3.3 Services
    • 5.4.3.4 Technology
    • 5.4.3.5 Application
    • 5.4.3.6 End User
    • 5.4.3.7 Deployment
    • 5.4.3.8 Stage
    • 5.4.3.9 Solutions
  • 5.4.4 Japan
    • 5.4.4.1 Type
    • 5.4.4.2 Product
    • 5.4.4.3 Services
    • 5.4.4.4 Technology
    • 5.4.4.5 Application
    • 5.4.4.6 End User
    • 5.4.4.7 Deployment
    • 5.4.4.8 Stage
    • 5.4.4.9 Solutions
  • 5.4.5 Australia
    • 5.4.5.1 Type
    • 5.4.5.2 Product
    • 5.4.5.3 Services
    • 5.4.5.4 Technology
    • 5.4.5.5 Application
    • 5.4.5.6 End User
    • 5.4.5.7 Deployment
    • 5.4.5.8 Stage
    • 5.4.5.9 Solutions
  • 5.4.6 Taiwan
    • 5.4.6.1 Type
    • 5.4.6.2 Product
    • 5.4.6.3 Services
    • 5.4.6.4 Technology
    • 5.4.6.5 Application
    • 5.4.6.6 End User
    • 5.4.6.7 Deployment
    • 5.4.6.8 Stage
    • 5.4.6.9 Solutions
  • 5.4.7 Rest of APAC
    • 5.4.7.1 Type
    • 5.4.7.2 Product
    • 5.4.7.3 Services
    • 5.4.7.4 Technology
    • 5.4.7.5 Application
    • 5.4.7.6 End User
    • 5.4.7.7 Deployment
    • 5.4.7.8 Stage
    • 5.4.7.9 Solutions
• 5.5 Europe Market Size (2020-2035)
  • 5.5.1 Germany
    • 5.5.1.1 Type
    • 5.5.1.2 Product
    • 5.5.1.3 Services
    • 5.5.1.4 Technology
    • 5.5.1.5 Application
    • 5.5.1.6 End User
    • 5.5.1.7 Deployment
    • 5.5.1.8 Stage
    • 5.5.1.9 Solutions
  • 5.5.2 France
    • 5.5.2.1 Type
    • 5.5.2.2 Product
    • 5.5.2.3 Services
    • 5.5.2.4 Technology
    • 5.5.2.5 Application
    • 5.5.2.6 End User
    • 5.5.2.7 Deployment
    • 5.5.2.8 Stage
    • 5.5.2.9 Solutions
  • 5.5.3 United Kingdom
    • 5.5.3.1 Type
    • 5.5.3.2 Product
    • 5.5.3.3 Services
    • 5.5.3.4 Technology
    • 5.5.3.5 Application
    • 5.5.3.6 End User
    • 5.5.3.7 Deployment
    • 5.5.3.8 Stage
    • 5.5.3.9 Solutions
  • 5.5.4 Spain
    • 5.5.4.1 Type
    • 5.5.4.2 Product
    • 5.5.4.3 Services
    • 5.5.4.4 Technology
    • 5.5.4.5 Application
    • 5.5.4.6 End User
    • 5.5.4.7 Deployment
    • 5.5.4.8 Stage
    • 5.5.4.9 Solutions
  • 5.5.5 Italy
    • 5.5.5.1 Type
    • 5.5.5.2 Product
    • 5.5.5.3 Services
    • 5.5.5.4 Technology
    • 5.5.5.5 Application
    • 5.5.5.6 End User
    • 5.5.5.7 Deployment
    • 5.5.5.8 Stage
    • 5.5.5.9 Solutions
  • 5.5.6 Rest of Europe
    • 5.5.6.1 Type
    • 5.5.6.2 Product
    • 5.5.6.3 Services
    • 5.5.6.4 Technology
    • 5.5.6.5 Application
    • 5.5.6.6 End User
    • 5.5.6.7 Deployment
    • 5.5.6.8 Stage
    • 5.5.6.9 Solutions
• 5.6 Middle East & Africa Market Size (2020-2035)
  • 5.6.1 Saudi Arabia
    • 5.6.1.1 Type
    • 5.6.1.2 Product
    • 5.6.1.3 Services
    • 5.6.1.4 Technology
    • 5.6.1.5 Application
    • 5.6.1.6 End User
    • 5.6.1.7 Deployment
    • 5.6.1.8 Stage
    • 5.6.1.9 Solutions
  • 5.6.2 United Arab Emirates
    • 5.6.2.1 Type
    • 5.6.2.2 Product
    • 5.6.2.3 Services
    • 5.6.2.4 Technology
    • 5.6.2.5 Application
    • 5.6.2.6 End User
    • 5.6.2.7 Deployment
    • 5.6.2.8 Stage
    • 5.6.2.9 Solutions
  • 5.6.3 South Africa
    • 5.6.3.1 Type
    • 5.6.3.2 Product
    • 5.6.3.3 Services
    • 5.6.3.4 Technology
    • 5.6.3.5 Application
    • 5.6.3.6 End User
    • 5.6.3.7 Deployment
    • 5.6.3.8 Stage
    • 5.6.3.9 Solutions
  • 5.6.4 Sub-Saharan Africa
    • 5.6.4.1 Type
    • 5.6.4.2 Product
    • 5.6.4.3 Services
    • 5.6.4.4 Technology
    • 5.6.4.5 Application
    • 5.6.4.6 End User
    • 5.6.4.7 Deployment
    • 5.6.4.8 Stage
    • 5.6.4.9 Solutions
  • 5.6.5 Rest of MEA
    • 5.6.5.1 Type
    • 5.6.5.2 Product
    • 5.6.5.3 Services
    • 5.6.5.4 Technology
    • 5.6.5.5 Application
    • 5.6.5.6 End User
    • 5.6.5.7 Deployment
    • 5.6.5.8 Stage
    • 5.6.5.9 Solutions

6 Market Strategy

• 6.1 Demand-Supply Gap Analysis
• 6.2 Trade & Logistics Constraints
• 6.3 Price-Cost-Margin Trends
• 6.4 Market Penetration
• 6.5 Consumer Analysis
• 6.6 Regulatory Snapshot

7 Competitive Intelligence

• 7.1 Market Positioning
• 7.2 Market Share
• 7.3 Competition Benchmarking
• 7.4 Top Company Strategies

8 Company Profiles

• 8.1 Blueprint Medicines
  • 8.1.1 Overview
  • 8.1.2 Product Summary
  • 8.1.3 Financial Performance
  • 8.1.4 SWOT Analysis
• 8.2 Adaptive Biotechnologies
  • 8.2.1 Overview
  • 8.2.2 Product Summary
  • 8.2.3 Financial Performance
  • 8.2.4 SWOT Analysis
• 8.3 Nant Health
  • 8.3.1 Overview
  • 8.3.2 Product Summary
  • 8.3.3 Financial Performance
  • 8.3.4 SWOT Analysis
• 8.4 G1 Therapeutics
  • 8.4.1 Overview
  • 8.4.2 Product Summary
  • 8.4.3 Financial Performance
  • 8.4.4 SWOT Analysis
• 8.5 C4 Therapeutics
  • 8.5.1 Overview
  • 8.5.2 Product Summary
  • 8.5.3 Financial Performance
  • 8.5.4 SWOT Analysis
• 8.6 Mirati Therapeutics
  • 8.6.1 Overview
  • 8.6.2 Product Summary
  • 8.6.3 Financial Performance
  • 8.6.4 SWOT Analysis
• 8.7 Relay Therapeutics
  • 8.7.1 Overview
  • 8.7.2 Product Summary
  • 8.7.3 Financial Performance
  • 8.7.4 SWOT Analysis
• 8.8 Immuno Gen
  • 8.8.1 Overview
  • 8.8.2 Product Summary
  • 8.8.3 Financial Performance
  • 8.8.4 SWOT Analysis
• 8.9 Harpoon Therapeutics
  • 8.9.1 Overview
  • 8.9.2 Product Summary
  • 8.9.3 Financial Performance
  • 8.9.4 SWOT Analysis
• 8.10 Cellectis
  • 8.10.1 Overview
  • 8.10.2 Product Summary
  • 8.10.3 Financial Performance
  • 8.10.4 SWOT Analysis
• 8.11 Iovance Biotherapeutics
  • 8.11.1 Overview
  • 8.11.2 Product Summary
  • 8.11.3 Financial Performance
  • 8.11.4 SWOT Analysis
• 8.12 Zymeworks
  • 8.12.1 Overview
  • 8.12.2 Product Summary
  • 8.12.3 Financial Performance
  • 8.12.4 SWOT Analysis
• 8.13 Repare Therapeutics
  • 8.13.1 Overview
  • 8.13.2 Product Summary
  • 8.13.3 Financial Performance
  • 8.13.4 SWOT Analysis
• 8.14 Arcus Biosciences
  • 8.14.1 Overview
  • 8.14.2 Product Summary
  • 8.14.3 Financial Performance
  • 8.14.4 SWOT Analysis
• 8.15 Black Diamond Therapeutics
  • 8.15.1 Overview
  • 8.15.2 Product Summary
  • 8.15.3 Financial Performance
  • 8.15.4 SWOT Analysis
• 8.16 Neoleukin Therapeutics
  • 8.16.1 Overview
  • 8.16.2 Product Summary
  • 8.16.3 Financial Performance
  • 8.16.4 SWOT Analysis
• 8.17 Fate Therapeutics
  • 8.17.1 Overview
  • 8.17.2 Product Summary
  • 8.17.3 Financial Performance
  • 8.17.4 SWOT Analysis
• 8.18 Allogene Therapeutics
  • 8.18.1 Overview
  • 8.18.2 Product Summary
  • 8.18.3 Financial Performance
  • 8.18.4 SWOT Analysis
• 8.19 Surface Oncology
  • 8.19.1 Overview
  • 8.19.2 Product Summary
  • 8.19.3 Financial Performance
  • 8.19.4 SWOT Analysis
• 8.20 Kura Oncology
  • 8.20.1 Overview
  • 8.20.2 Product Summary
  • 8.20.3 Financial Performance
  • 8.20.4 SWOT Analysis

9 About Us

• 9.1 About Us
• 9.2 Research Methodology
• 9.3 Research Workflow
• 9.4 Consulting Services
• 9.5 Our Clients
• 9.6 Client Testimonials
• 9.7 Contact Us